Kyverna Therapeutics, Inc. (KYTX)
Nasdaq · Healthcare · Biotechnology
$6.32+1.61%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $391M
- 52-week range
- $5.30 – $13.67
- 52-week change
- +5.60%
- EPS (trailing)
- −$2.93
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$161M
- Diluted EPS
- −$3.64
- Free cash flow
- −$154M
From the company’s annual report on SEC EDGAR.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Headquarters: EmeryVille, United States · 149 employees · kyvernatx.com